Table 5, Median treatment ranks and probability of being the best treatment for all interventions for PPH ≥ 1000mL, vaginal birth subgroup - Evidence reviews for uterotonics for the prevention of postpartum haemorrhage - NCBI Bookshelf

Warning: The NCBI web site requires JavaScript to function. more...

Table 5Median treatment ranks and probability of being the best treatment for all interventions for PPH ≥ 1000mL, vaginal birth subgroup

Intervention	Median (95% CrI) treatment rank	Probability of being best
Carboprost	2 (1, 11)	23.14%
Misoprostol >600 mcg and ≤ 800 mcg	2 (0, 12)	57.63%
Ergometrine plus oxytocin	4 (2, 7)	1.10%
Carbetocin	5 (2, 9)	1.17%
Misoprostol plus oxytocin	5 (1, 10)	1.39%
Ergometrine	4 (1, 11)	4.66%
Oxytocin >1 IU and ≤ 5 IU	7 (2, 10)	0.39%
Oxytocin >5 IU and ≤ 10 IU	7 (4, 10)	0.00%
Oxytocin ≤1 IU	10 (1, 12)	9.95%
Misoprostol ≤ 600 mcg	9 (6, 11)	0.00%
Oxytocin > 10 IU	10 (3, 12)	0.57%
Placebo	11 (10, 12)	0.00%

: Misoprostol >800 mcg and ≤ 1000 mcg is excluded from the ranking due to highly uncertain estimates.

From: Evidence reviews for uterotonics for the prevention of postpartum haemorrhage

Cover of Evidence reviews for uterotonics for the prevention of postpartum haemorrhage

Evidence reviews for uterotonics for the prevention of postpartum haemorrhage: Intrapartum care: Evidence review M.

NICE Guideline, No. 235.

London: National Institute for Health and Care Excellence (NICE); 2023 Sep.

Copyright © NICE 2023.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.